Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA292278
Max Phase: Preclinical
Molecular Formula: C8H10N2O5
Molecular Weight: 214.18
Molecule Type: Small molecule
Associated Items:
ID: ALA292278
Max Phase: Preclinical
Molecular Formula: C8H10N2O5
Molecular Weight: 214.18
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1ccn([C@H]2CO[C@@H](CO)O2)c(=O)[nH]1
Standard InChI: InChI=1S/C8H10N2O5/c11-3-7-14-4-6(15-7)10-2-1-5(12)9-8(10)13/h1-2,6-7,11H,3-4H2,(H,9,12,13)/t6-,7-/m1/s1
Standard InChI Key: MYQDAUKUBLHXLX-RNFRBKRXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 214.18 | Molecular Weight (Monoisotopic): 214.0590 | AlogP: -1.60 | #Rotatable Bonds: 2 |
Polar Surface Area: 93.55 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.70 | CX Basic pKa: | CX LogP: -0.94 | CX LogD: -0.94 |
Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.62 | Np Likeness Score: 0.73 |
1. Wilson LJ, Choi W, Spurling T, Liotta DC, Schinazi RF, Cannon D, Painter GR, St. Clair M, Furman PA. (1993) The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides, 3 (2): [10.1016/S0960-894X(01)80870-2] |
2. Kim HO, Ahn SK, Alves AJ, Beach JW, Jeong LS, Choi BG, Van Roey P, Schinazi RF, Chu CK.. (1992) Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity., 35 (11): [PMID:1597854] [10.1021/jm00089a007] |
3. Lee M, Chu CK, Balakrishna Pai S, Zhu Y, Cheng Y, Chun MW, Chung WK. (1995) Dioxolane cytosine nucleosides as anti-hepatitis B agents, 5 (17): [10.1016/0960-894X(95)00343-R] |
4. Lin JS, Kira T, Gullen E, Choi Y, Qu F, Chu CK, Cheng YC.. (1999) Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents., 42 (12): [PMID:10377226] [10.1021/jm9806749] |
Source(1):